Estee Lauder beats Q4 estimates, lifts FY27 sales guidance
Estee Lauder reports better-than-expected fourth-quarter results, with adjusted earnings of 39 cents a share versus 32 cents expected and sales of $3.63 billion versus $3.54 billion expected, while FY27 sales guidance midpoint tops estimates.
S. stocks were mixed, with the Dow Jones index gaining over 200 points on Wednesday. Shares of Estee Lauder Companies Inc (NYSE: EL ) rose sharply after the company reported better-than-expected fourth-quarter financial results and issued its FY27 sales guidance with its midpoint above estimates. Adjusted earnings were 39 cents per share, beating the analyst estimate of 32 cents.
The Middle East conflict reduced adjusted earnings by 5 cents per share. However, tariff refunds provided a 7-cent benefit. 54 billion analyst estimate. Organic net sales increased 5%.
15 on Wednesday. Here are some other big stocks recording gains in today’s session. 70 after the company and Merck announced topline results from the Phase 3 INTerpath-001 trial met its primary and a key secondary endpoint. 64.
01. 89. 47. 49.
BMO Capital analyst David Lebowitz initiated coverage on Prime Medicine with an Outperform rating and announced a price target of $9. 62. 82. 36.
93. 43 after the company announced topline results from the Phase 3 INTerpath-001 trial. The trial met its primary and key secondary endpoint. 43.
18. 17. 00. 58.
92. 04 following an SEC Form 8-K filing disclosing a major commercial agreement and warrant deal with Google. 43. Photo via Shutterstock